EICHOR
● Completed
An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)
Condition: Primary Immunodeficiency · Sponsor: CSL Behring
About this study
This is an open-label, multicenter, phase 4 study in IG treatment-naïve participants with PID, conducted in the United States (US), to assess the PK, safety, and tolerability of IgPro20. The primary objective of this study is to characterize the PK of IgPro20 and to assess the safety and tolerability of IgPro20 in IG treatment-naïve participants with PID who are aged greater than or equal to (\>=) 18 years.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (8)
| Research Solutions of AZ | Litchfield Park, Arizona, United States | — |
| Medical Research of Arizona | Scottsdale, Arizona, United States | — |
| Immunoe Health Centers | Centennial, Colorado, United States | — |
| Johns Hopkins Bayview Medical Center | Baltimore, Maryland, United States | — |
| Midwest Immunology | Plymouth, Minnesota, United States | — |
| Washington University | St Louis, Missouri, United States | — |
| Allergy, Asthma and Clinical Research Center | Oklahoma City, Oklahoma, United States | — |
| Allergy & Clinical Immunology | Pittsburgh, Pennsylvania, United States | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07076446